Methods and process

ACE Clinical Guideline (ACG) methods and process

Clinical guidelines are important knowledge tools that summarise evidence and present recommendations to support clinical decision-making. Their purpose ranges from improving effectiveness and quality of care, to decreasing unnecessary variations in practice and decreasing costly preventable mistakes and adverse events.

Trustworthy clinical guidelines are “…the cornerstone of giving evidence-informed advice in response to clinical, public health and health policy questions. They address those questions by using the best available evidence and transparently integrating the judgements of experts and the input of stakeholders in the process” (WHO Handbook for guideline contextualization, 2023).

The Evidence to Practice Office (ETPO) in ACE develops ACE Clinical Guidelines (ACGs), which carefully balance evidence-based best practices and local feasibility considerations – to provide a set of clinical recommendations tailored to Singapore’s context. ETPO employs a rigorous and systematic process for the development of ACGs, as summarised in Figure 1 below.

Figure 1: ACG development process

Access the ACG Manual at the link below for a detailed description of each of the above steps, including targeted dissemination of final ACG contents.

Download the ACE Clinical Guideline Methods and Processes Manual (May 2025)

Health technology evaluation methods and processes

What is health technology assessment (HTA)?

HTA is an established scientific research methodology to inform policy and clinical decision-making on the relative value of new health technologies, such as drugs, devices and medical services, compared to existing standards of care. It is conducted using analytical frameworks, drawing on clinical, epidemiological and health economic information to determine how best to allocate limited healthcare resources.

HTA helps to answer the following questions:

1. Does the health technology work?

2. What benefit does it provide and for whom?

3. What does it cost (to the healthcare service, to the patient, etc.), including opportunity costs?

4. How does it compare with the available alternatives?

The goal of HTA is to inform the development of effective health policies about the use of health technologies in a manner that is patient-focused and achieves best value. ACE conducts HTAs to support subsidy decisions by the respective MOH advisory committees for two main technology streams:

1. Drugs: Drug Advisory Committee (DAC)

2. Medical technologies (including devices, diagnostics and medical services): Medical Technology Advisory Committee (MTAC).

There are currently 3 main process steps which ACE follows when evaluating health technologies to inform decision-making:

1. Topic submission and selection
   A call for applications is put out annually to the public healthcare institutions to submit requests for subsidy consideration. ACE works with the DAC and MTAC to select the topics for evaluation.
   

2. Technical evaluation
   Once a topic is selected, technical evaluations are conducted at 2 levels – expedited or full – depending on the estimated budget impact and uncertainty around the clinical and cost parameters for each technology. In the case of medical technologies, the complexity of the care pathway incorporating the use of the technology is also taken into consideration when deciding the type of evaluation. Most of the evaluations are conducted internally by the technical teams in ACE, with supporting evidence provided by local clinical experts and companies. Value-based pricing is conducted in parallel with technology evaluations, if required, to ensure that the price of the technology recommended for subsidy represents a cost-effective use of healthcare resources and is commensurate with the technology's value in Singapore's context. Under this process, companies are invited to submit their best cost prices for their technologies, which will inform ACE's cost-effectiveness analyses and budget impact assessments.
   
   i. Higher cost technologies (estimated budget impact >$2 million a year) are typically subject to full evaluation which includes a systematic review of the clinical evidence, and economic modelling to estimate the cost-effectiveness of the technologies in the local context (where feasible);
   
   ii. Technologies with lower budget impact are subject to expedited evaluations (without modelling), which are usually informed by published clinical evidence and international cost-effectiveness studies.

3. Decision-making
   The evidence in ACE's technical evaluations informs the committees' subsidy deliberations around 4 core decision-making criteria:
   
   i. Clinical need of patients and nature of the condition
   
   ii. Clinical effectiveness and safety of the technology
   
   iii. Cost-effectiveness (value for money) – the incremental benefit and cost of the technology compared to existing alternatives
   
   iv. Estimated annual cost of the technology and the number of patients likely to benefit from the technology
   
   A 5^th criterion is also considered for medical technologies:
   v. Organisational feasibility – the potential impact of adopting the technology to the healthcare system
   
   Other factors, including social, ethical and value judgments, may also inform the committees' considerations.
   
   On the basis of the available evidence, the committees recommend whether government subsidy should be given for a health technology through the respective financing scheme.

ACE's Drug and Vaccine Evaluation Methods and Process Guide (Version 3.1) and Medical Technologies Methods and Process Guide (Version 1) outline the core processes and methods underpinning ACE's assessment of clinical and economic evidence, and any other important factors impacting the adoption of the technologies, which are being considered for government subsidy. The guides also document value-based pricing processes and the committees' decision-making frameworks.

Position statement on real-world data and evidence (RWD/RWE)

As the regulatory landscape evolves and healthcare data capabilities advance, health technology assessment (HTA) agencies globally are increasingly recognising the role of real-world data (RWD) and real-world evidence (RWE) in complementing evidence from randomised controlled trials (RCTs) and addressing evidence gaps.

This position statement sets out ACE’s approach to the use of RWD and RWE in HTA, including the contexts in which such evidence may be needed or valuable for evaluating health technologies.

It provides guidance for researchers, healthcare professionals, and industry stakeholders involved in collecting data, generating or submitting evidence to inform funding decisions in Singapore.

Download Position statement on real-world data and evidence (RWD/RWE)

Drug and Vaccine Evaluation methods and process guide

Download ACE Drug and Vaccine Evaluation methods and process guide (Sep 2023) [PDF, 1 MB]

Download Costing template (Jul 2024) [XLXS, 2.5 MB]

Company submissions to ACE

Since 1 January 2021, pharmaceutical companies have been able to request for their products to be evaluated for funding consideration under the company-led process. Companies are responsible for providing an evidence submission to ACE, to support the MOH Drug Advisory Committee’s deliberations.

The aim of this process is to enable medicines to be evaluated close to the anticipated date of regulatory approval by the Health Sciences Authority (HSA) and expedite funding considerations to improve patient access to clinically necessary treatments.

This process is the default approach for listing new cancer treatments (or new indications of existing cancer treatments) on the MOH Cancer Drug List. From 2024 onwards, ACE will also accept submissions for selected non-cancer drugs and cell, tissue and gene therapy products (CTGTPs) for listing on the MOH List of Subsidised Drugs and MOH CTGTP List, respectively.

Companies should refer to the key processes deadlines below for evidence submissions and pricing resubmissions to be reviewed at the respective 2026/2027 DAC meetings. From 2024 onwards, companies should also submit a completed costing template with the pre-submission form when registering intent to put in a submission.

Companies are expected to follow the Procedures and Guidelines for Company Submissions to the Agency for Care Effectiveness for Funding Consideration and its accompanying resources when preparing an evidence submission. Information on the fees for company submissions can be found in the Charging Procedure for Review of Company Evidence Submissions to the Agency for Care Effectiveness.

• Download Procedures and guidelines for company submissions (Oct 2024) [PDF, 2 MB]

• Download Charging Procedure for Company Submissions to ACE (7 Jan 2025) [PDF, 139 KB]

• Download Costing Template (July 2024) [XLXS, 2.5 MB]

• Download Deed Template (Feb 2025) [DOCX, 92.1 KB]

• Download Singapore Healthcare Resource Sheet (Oct 2024) [XLXS, 39 KB]

• Download Company presubmission form (Dec 2024) [DOCX, 61 KB]

• Download Request for proposal template (Nov 2025) [DOCX, 1.25 MB]

• Download Company Response Template (Oct 2023) [PDF, 124 KB]

Horizon Scanning methods and process guide

Download ACE Horizon Scanning methods and process guide (Mar 2024). [PDF, 484 KB]

Industry notification of pipeline medical technologies for horizon scanning

Companies may submit their pipeline medical technologies intended to be introduced into Singapore to provide early visibility of their technologies to MOH. This may be used to assist in the early planning and, if appropriate, their early adoption into the local public healthcare institutions. There are no immediate funding implications resulting from the horizon scanning assessment, if any, of the submitted technologies.

The scope of medical technologies for the Industry Notification includes medical devices, diagnostics, services, procedures or medical-related digital health technologies (e.g. mobile apps, online tools, artificial intelligence software) intended to be introduced locally. These includes medical technologies that are intended to be submitted to or have been submitted to the Health Sciences Authority (HSA). Medical technologies registered with HSA are not accepted.

Submission of pipeline medical technologies

The annual submission window is open from 1st May to 31st May each year, both dates inclusive. Announcement will be made on ACE’s website one week prior to the submission window. Companies may share their pipeline technologies with ACE through the notification form. Submissions should be made to the horizon scanning team at ACE_HS@moh.gov.sg within the submission window no later than 31st May.

Download Industry Notification Form for Horizon Scanning [XLXS, 26 KB]

Medical Technology methods and process guide

Download ACE Medical Technology Evaluation methods and process guide (Dec 2025) [PDF, 1.8 MB]

Download Company Evidence Submission Template for Med Tech (Mar 2024) [DOCX, 32 KB]

Medical Technology Model Update Process (MUP)

The Model Update Process (MUP) allows companies to request for their products to be evaluated for subsidy listing on the Implant Subsidy List (ISL). Applications are accepted during three annual windows: 1^st – 15^th of April, August, and December.

The MUP is open to companies that have implants in onboarded categories (Refer to on-boarding schedule below).

Companies may write to ACE at  MOH_ACE_Medtech@moh.gov.sg to enquire about eligibility and application requirements.

Companies should refer to the key process milestones below for expected evaluation timelines and deadlines for applications and return of signed agreements/contracts. To ensure expedient evaluations and processing of applications, companies are encouraged to provide clear information and adhere to the stipulated timelines and templates when submitting MUP application forms and/or corresponding with ACE. Failure to adhere to the instructions on the application forms can result in the delay or rejection of the application for subsidy consideration.

Glossary list

Download ACE Glossary list (updated May 2023) [PDF, 389 KB]

Video resource

Take a look at how ACE conducts HTA!